Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancer Prevention

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...

Comparing the Survival Analysis of Two or More Groups

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and Cox...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Trophoblastic-Differentiated Urothelial Carcinoma: Real-World Sequencing and Clinical Implications.

Clinical genitourinary cancer·2026

Same author

External Validation of the International Bladder Cancer Group Intermediate-risk Non-muscle-invasive Bladder Cancer Substratification Model.

European urology oncology·2026

Same author

Superficial Cervical Plexus Block and Quality of Recovery after Thyroidectomy: A Randomized Clinical Trial.

Anesthesiology·2026

Same author

A Rare Case of Four-year Complete Metabolic Response in Multisystem Anti-Jo-1 Antisynthetase Syndrome Assessed by 18F-FDG PET/CT.

Clinical nuclear medicine·2026

Same author

Epidemiological Trends and Germline Variant Analysis of Young-Onset Bladder Cancer.

Clinical genitourinary cancer·2026

Same author

Trends in the diagnosis of variant bladder cancer: a national retrospective cohort analysis.

Frontiers in oncology·2026

Same journal

Editorial Comment on "A Histopathologic Assessment of Prostate Ductal Anatomy in Relation to Micro-Ultrasound".

Urology·2026

Same journal

Same-Day Discharge Following Multiport Robot-Assisted Simple Prostatectomy: A Prospective Feasibility Study of Outcomes, Costs, and Post-Discharge Healthcare Utilization.

Urology·2026

Same journal

Extended versus Standard Lymph Node Dissection at the Time of Radical Cystectomy for Bladder Cancer.

Urology·2026

Same journal

Intractable Epistaxis and Severe Hypertension in a Young Woman.

Urology·2026

Same journal

A 53-Year-Old Man with Elevated PSA and a Cystic Pelvic Lesion.

Urology·2026

Same journal

Low-Grade, Papillary Bladder Tumors A plea for in-office fulguration.

Urology·2026

See all related articles

Search research articles

Related Experiment Video

Updated: May 12, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Sociodemographic Factors Associated With Tissue-based Genomic Testing for Prostate Cancer.

Gabriela M Diaz¹, Nethusan Sivanesan¹, Sebastien Strachan²

¹Yale School of Medicine, Department of Urology, New Haven, CT.

|December 18, 2025

Summary

This summary is machine-generated.

Genomic classifier testing for prostate cancer is less common in socially disadvantaged areas and among Hispanic patients. These findings reveal demographic disparities in accessing advanced risk assessment tools.

More Related Videos

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Related Experiment Videos

Last Updated: May 12, 2026

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Use of Magnetic Resonance Imaging and Biopsy Data to Guide Sampling Procedures for Prostate Cancer Biobanking

Published on: October 10, 2019

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

Area of Science:

Oncology
Health Services Research
Genomics

Background:

Genomic classifiers (GC) aid in risk stratification for localized prostate cancer (PCa).
Factors influencing GC adoption in PCa management are not well understood.
Personalized treatment decisions for PCa can be enhanced by GC testing.

Purpose of the Study:

To investigate the association between sociodemographic factors and GC testing for localized PCa.
To identify patient and area-level predictors of GC utilization in PCa care.

Main Methods:

Retrospective analysis of localized PCa patients (2012-2022) who received genomic testing.
Inclusion of clinical, Area Deprivation Index (ADI), and health insurance data.
Logistic regression models to assess the relationship between ADI and GC test receipt.

Main Results:

40.1% of 2103 eligible patients underwent GC testing.
Higher GC testing rates were observed in less deprived areas (40.9%) versus most deprived (34.6%).
Increased area deprivation, Hispanic ethnicity, and younger age were linked to lower GC test odds.

Conclusions:

Genomic testing utilization for PCa is lower in socioeconomically disadvantaged populations and Hispanic patients.
Demographic variations in the use of discretionary PCa risk assessment tools are evident.
Addressing disparities in GC testing access is crucial for equitable PCa management.